West Pharmaceutical Services, Inc.
NYSE:WSTMedical - Instruments & Supplies
+$5.04 today
- Market cap
- $28.14B
- Beta
- 1.18
- P/E (TTM)
- 43.6
- EPS (TTM)
- $7.54
- Dividend yield
- 0.26%
Volume 0.59M
Average 0.85M
WST EBITDA Margin
EBITDA as a percentage of revenue.
West Pharmaceutical Services, Inc.NYSE: WST
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin holds steady near 25.8%
EBITDA Margin was 25.8% in Q2 FY2026, down 0.1 pp from a year earlier. On a trailing-twelve-month basis it was 26.2%, up 0.5 pp year over year. Over 3 fiscal years it narrowed by 2.9 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 12 analysts of 30.1% for the fiscal year ending Dec 2026, up from 25.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 25.8%-0.0 pp QoQ
- Last fiscal yearDec 2025
- 25.1%-0.6 pp YoY
- LTMJun 2026
- 26.2%+0.5 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -0.1 pp | +1.3 pp | +1.3 pp |
| 1 year | -0.6 pp | +5.0 pp | +5.7 pp |
| 3 years | -2.9 pp | +7.7 pp | +10.7 pp |
| 5 years | +11.5 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 25.1%
- Year-over-year change
- -0.6pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.1% | -0.6pp |
| FY2024 | 2024-12-31 | 25.7% | -2.9pp |
| FY2023 | 2023-12-31 | 28.6% | +0.6pp |
| FY2022 | 2022-12-31 | 28.0% | -3.1pp |
| FY2021 | 2021-12-31 | 31.1% | — |
EBITDA Margin vs competitors
How WST compares with its peers on the latest reported figures
- WST's LTM Jun 2026 EBITDA Margin of 26.2% is the highest of the 5 companies compared; the peer median is 16.2%.
- Its year-over-year change of +0.5 pp is the highest of 5, against a peer median of -2.5 pp.
- Over three fiscal years its change of -2.9 pp compares with a peer median of +4.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 26.2% | +0.5 pp | -2.9 pp | |
| LTM Jun 2026 | 24.3% | -2.8 pp | -0.4 pp | |
| LTM Jun 2026 | 20.9% | -1.5 pp | +3.7 pp | |
| LTM Jun 2026 | 11.5% | -2.1 pp | +5.5 pp | |
| LTM Mar 2026 | -7.5% | -19.9 pp | +166.6 pp | |
| Peer median (excluding WST) | 16.2% | -2.5 pp | +4.6 pp | |
Competitors are the stored peer set for WST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.83B | 2.89B | 2.95B | 2.89B | 3.07B |
| Cost of Revenue | 1.66B | 1.75B | 1.82B | 1.89B | 1.97B |
| Gross Profit | 1.17B | 1.14B | 1.13B | 1B | 1.1B |
| Gross Margin | 41.5% | 39.5% | 38.4% | 34.6% | 35.9% |
| Research & Development | 52.8M | 58.5M | 68.4M | 69.1M | 74.3M |
| Selling, General & Admin | 361.9M | 316.9M | 353.4M | 338.5M | 393.1M |
| Operating Expenses | 414.7M | 375.4M | 421.8M | 407.6M | 485.9M |
| Depreciation & Amortization | 122.3M | 120.6M | 137.3M | 155.4M | 171.4M |
| EBITDA | 879.7M | 808.1M | 844.1M | 743.8M | 770.6M |
| EBITDA Margin | 31.1% | 28.0% | 28.6% | 25.7% | 25.1% |
| Operating Income | 758.7M | 763.5M | 710.9M | 594.6M | 617.4M |
| Operating Margin | 26.8% | 26.5% | 24.1% | 20.6% | 20.1% |
| Interest Income | 1M | 5.1M | 28M | 19.6M | 17.7M |
| Interest Expense | 8.5M | 7.6M | 8.8M | 2.9M | 600K |
| Other Income / Expenses | 10.3M | (62.9M) | 4.8M | 5.6M | (2.1M) |
| Income Before Tax | 769M | 700.6M | 715.7M | 600.2M | 615.3M |
| Pre-Tax Margin | 27.2% | 24.3% | 24.3% | 20.7% | 20.0% |
| Income Tax Expense | 107.2M | 114.7M | 122.3M | 107.5M | 121.6M |
| Net Income | 661.8M | 585.9M | 593.4M | 492.7M | 493.7M |
| Net Margin | 23.4% | 20.3% | 20.1% | 17.0% | 16.1% |
| EPS (Basic) | 8.90 | 7.88 | 7.99 | 6.75 | 6.83 |
| EPS (Diluted) | 8.67 | 7.73 | 7.88 | 6.69 | 6.80 |
| Weighted Avg Shares | 74.4M | 74.4M | 74.3M | 73M | 72.3M |
| Weighted Avg Shares (Diluted) | 76.3M | 75.8M | 75.3M | 73.7M | 72.7M |
West Pharmaceutical Services, Inc.
NYSE:WST
Intrinsic Alpha fair value
Locked
Current Price
$404.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.